Market Regional Insights
North America is expected to hold
dominant position in Bioreactors
Market due to presence of major biopharmaceutical manufacturing companies.
Biopharmaceutical companies such as Gilead Science, Inc., Amgen, and Biogen,
Inc. in the U.S. actively conducts research on novel therapies for the
treatment of various diseases. Research of therapies associated with oncology
such as monoclonal antibodies require usage of bioreactors on small as well as
large scale for production purposes. Furthermore, according to the National
Centre for Biotechnology Information (NCBI), in 2014, 65.6% of the clinical
scale manufacturers and around 42% of the commercial manufacturers used
single-use bioreactors to improve their bioprocessing. Europe is expected to
witness significant growth rate in the bioreactors market due to increasing
usage of bioreactors in biopharmaceutical companies. According to the
Organization for Economic Co-operation and Development (OECD), in 2015, around
1,700 biopharmaceutical companies, which utilize bioreactors, are from Europe.
Bioreactor is an engineered or
manufactured vessel that is used in the production of wide range of biological
products. Industrial bioreactor is a vessel in which biochemical process is
carried out using microbes and animal cells or biologically active compounds
that are derived from living cells. Bioreactors are cylindrical in shape with
capacity of liters to cubic meters and is the most important component involved
in bioprocessing. Fermentation processes such as wine, and beer production are
carried out in bioreactors. Bioreactors for large scale production of therapeutic
products are made of stainless steel. In biopharmaceutical companies, small
glass bioreactors are used for research and development purpose and for scale
up activities. Another type of bioreactors are disposable bioreactors, which
are meant for single use and hence are called as single-use bioreactors. It is
generally used for extensive research and manufacturing. Bioreactors can
operate in batch, fed batch, and continuous stirred tank processes. Bioreactors
are used to produce therapeutics, which include monoclonal antibodies,
vaccines, stem cells, and gene modified cells.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1593
Market Drivers
The efficiency of single-use
bioreactors has increased across pharmaceutical industries in terms of
production, quality control, and procurement. Single-use bioreactors offer
advantages such as consistency in production, increase in speed of manufacturing,
reduced operational cost, and reduction in manufacturing time of finished
dosage form, which foster growth of bioreactors market. In 2016, as per the
National Centre for Biotechnology Information (NCBI), operational cost per gram
of monoclonal antibody production (mAb) for single-use bioreactor is around 22%
lower than conventional system, mainly due to less labor, utilities,
maintenance, and waste. For commercial scale of monoclonal antibody production
(mAb), conventional fed-batch bioreactors usually require 10000L – 25000L
stainless steel tank to culture cells and produce yield of 2-6 g/L. However,
single-use bioreactors employ continuous cell culture supply in 500L - 2000L
tank and produces 10 - 30 times higher cell density. Therefore, more quantity of
products can be produced by using this single-use bioreactors, with less space
and capital cost. Other factors that
contribute to growth of the market include low water usage by single-use
systems, less floor space requirement, and low risk of cross contamination in
single-use system. Furthermore, in 2016, a case study by Cambridge Healthtech
Institute stated that by using single-use (SU) bioreactors, there can be an
annual savings of US$ 250,000 in water generation for injections and US$ 60,000
in labor time required to set up and cleaning of stainless steel tank. These
factors are expected to drive growth of the bioreactors market over the
forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/bioreactors-market-1593
Moreover, in bioprocessing,
enzymes used are specific in their action and produce a pure product. Diseases
such as diabetes and anemia are widespread globally, and according to the World
Health Organization (WHO), in 2014, around 415 million people were living with
diabetes, which indicates the need for increasing availability of bioprocessed
products at faster rates, wherein, advanced bioreactors could be useful. For
instance, bioprocessed products such as Amaryl manufactured by Sanofi Aventis
U.S. Llc, and Acarbose by Emcure Pharmaceutical Ltd. are used as anti-diabetic
drugs. Thus, implementation of single-use bioreactors has made clinical and
commercial production of biopharmaceuticals fast and efficient in limited time
and has reduced the cost associated with production, in turn driving growth of
bioreactors market.
Key players operating in
bioreactors market include Thermo Fisher Scientific, Inc., Merck KGaA, GE
Healthcare, Pall Corporation, ZETA Holdings GmbH, Sartorius AG BBI, Solaris,
Praj HiPurity Systems Limited, BiOENGiNEERiNG, INC., Infors AG, and Appplikon
Biotechnology, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1593
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment